G1 Therapeutics (NASDAQ:GTHX) Earning Somewhat Positive Press Coverage, Analysis Finds

News stories about G1 Therapeutics (NASDAQ:GTHX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. G1 Therapeutics earned a daily sentiment score of 0.00 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.2246735780943 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of G1 Therapeutics (NASDAQ:GTHX) traded down $0.34 during trading hours on Friday, hitting $22.97. The company had a trading volume of 36,335 shares, compared to its average volume of 85,884. G1 Therapeutics has a twelve month low of $12.04 and a twelve month high of $28.67. The stock has a market capitalization of $641.59 and a price-to-earnings ratio of -10.68.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.01. equities analysts anticipate that G1 Therapeutics will post -2.72 EPS for the current year.

A number of analysts have recently issued reports on GTHX shares. Zacks Investment Research lowered G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Cowen restated a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, November 8th. BTIG Research started coverage on G1 Therapeutics in a report on Tuesday, December 19th. They issued a “buy” rating and a $38.00 target price for the company. Finally, BidaskClub upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $31.40.

In other G1 Therapeutics news, Director Fredric N. Eshelman bought 250,000 shares of the stock in a transaction on Monday, November 13th. The shares were purchased at an average cost of $19.73 per share, with a total value of $4,932,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajesh Malik sold 3,776 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $22.96, for a total transaction of $86,696.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 545,932 shares of company stock valued at $10,848,385.

COPYRIGHT VIOLATION WARNING: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/04/g1-therapeutics-gthx-receiving-somewhat-positive-press-coverage-study-finds.html.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply